AIG Hospitals to Bring Cutting-Edge ZAP-X® Gyroscopic Radiosurgery® to South India
Stereotactic Radiosurgery (SRS), widely accepted as an alternative to conventional brain surgery for many patients, is an incision-free outpatient procedure offering surgical-like precision with no anesthesia, and minimal recovery time. However, access to SRS has remained limited globally due to high infrastructure costs and radiation safety challenges. With ZAP-X, AIG Hospitals addresses these constraints while placing India on the global map of next-generation neurosurgical care.
'At AIG, our unwavering mission has always been to bring the most advanced, evidence-backed, and patient-focused medical technologies to India,' said Dr. D Nageshwar Reddy, Chairman, AIG Hospitals. 'The addition of ZAP-X exemplifies this vision. We believe this technology will be a game-changer for patients across India and neighboring regions who can now access world-class radiosurgery without the burden of travel, hospitalization, or surgical recovery.'
Developed by Dr. John R. Adler, former Stanford professor of neurosurgery and radiation oncology, the ZAP-X platform is the world's first vault-free radiosurgery system, enabling installation without the need for costly radiation-shielded rooms. It also eliminates reliance on traditional Cobalt-60 radioactive sources, using a modern linear accelerator to deliver biologically consistent and efficient radiation doses.
'The strategic investment in ZAP-X is a reflection of our long-term vision to serve as a quaternary referral center for complex neurosurgical care, not only for India but for Southeast Asia, the Middle East, and Africa,' said Mr. PVS Raju, Vice-Chairman, AIG Hospitals. 'This platform expands our ability to handle high volumes with greater precision, while preserving patient quality of life through non-invasive care.'
Built with a gyroscopic, dual-gimbaled design, ZAP-X offers a large spherical workspace to precisely direct radiation beams from thousands of potential angles and thereby reduce dose concentrations within healthy brain tissue. Along with real-time imaging, ultra-low scatter radiation, and sub-millimeter targeting accuracy, these novel advancements aim to improve outcomes for patients with brain metastases, meningiomas, acoustic neuromas, arteriovenous malformations, and trigeminal neuralgia.
At the heart of this development lies AIG's Neurosurgical Program, led by Dr. Subodh Raju, Director & HOD, Neurosurgery, whose team will spearhead the clinical deployment of ZAP-X.
'ZAP-X is not just a technological upgrade, it is a paradigm shift,' said Dr. Subodh Raju. 'It enables us to precisely target even the most complex lesions while sparing healthy brain tissue. Patients walk in, undergo the pain-free session in a day-care setup, and walk out without hospitalization, or post-op recovery. This is the future of brain tumor treatment, and it will be now available in Hyderabad.' He added, 'The ability to offer repeat treatments when needed, patient-friendly immobilization without the rigid head frames of the past, and real-time dose monitoring puts this system at the forefront of radiosurgical safety and patient comfort.'
With ZAP-X, AIG Hospitals strengthens its position as a neuroscience leader and becomes part of an elite global network of early adopters of this technology. This move aligns with the hospital's larger vision to bridge the gap between cutting-edge research and clinical practice while ensuring equitable access to life-saving innovations.
About ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.
About AIG Hospitals
AIG Hospitals, Gachibowli is one of India's largest tertiary care, multi-specialty hospitals. With its 1000-bed capacity, 400+ consultant doctors and over 40 medical and surgical specialties, the hospital caters to more than 800,000 patients annually coming from all across India, Southeast Asia, Middle East and Africa. AIG is among only a few private hospitals in the country to have a fully functional Translational Research Facility where active bench to bedside research is undertaken in collaboration with many international and national institutes. Apart from being the highest volume center for Gastroenterology in the world with more than 30,000 therapeutic procedures, AIG centers of excellence include Cardiac Sciences, Neurosciences, Pulmonary Medicine, Oncology, and Renal and Bladder Sciences.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
AM Best Affirms Credit Ratings of Jordan Insurance Company Plc.
LONDON--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating of B (Fair) and the Long-Term Issuer Credit Rating of 'bb+' (Fair) of Jordan Insurance Company Plc. (JIC) (Jordan). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect JIC's balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, neutral business profile and marginal enterprise risk management (ERM). JIC's balance sheet strength is underpinned by its risk-adjusted capitalisation, which was at the strongest level as at year-end 2024, as measured by Best's Capital Adequacy Ratio (BCAR). The company's BCAR scores have improved in recent years as a result of measures taken by management to increase risk-adjusted capitalisation, including the suspension of dividend payments and the divesture of certain capital-intensive investments. Nonetheless, a partially offsetting rating factor is JIC's significant holdings of illiquid equity and real estate asset classes, which have been a source of volatility to the company's total equity, and have negatively impacted its regulatory solvency capital ratio. The ratings also consider JIC's moderately high reinsurance dependence for large property and commercial risks, although the associated risks are partially mitigated by a stable reinsurance panel of good credit quality. JIC has a track record of adequate operating performance, evidenced by return-on-equity ratios of approximately 4% over the last five years (2020-2024). The company reported a net profit of JOD 2.3 million in 2024 (2023: JOD 1.8 million), primarily driven by the profitability of its life portfolio, while challenging market conditions in Jordan and the United Arab Emirates translated into a non-life net/net combined ratio of 100.8% (101.7% in 2023 - as calculated by AM Best). Overall operating results have been supported by modest investment income, which translated into an average net investment return of 2.2% over the past five years. However, volatility in fair value movements of investments recognised through other comprehensive income introduced volatility into JIC's total equity over the period. JIC has an established position in Jordan's insurance market, where the company consistently ranks second based on gross written premiums; however, this market remains relatively small by international standards. JIC's insurance services revenue is well-diversified across a range of life and non-life business lines in Jordan. Due to the heavy use of reinsurance on property and other commercial lines, the company's net insurance services revenue is concentrated in motor and medical, although to a lesser extent than its domestic peers. The assessment considers the geographic diversification provided by branch offices in the UAE and, to a lesser extent, Kuwait, together with the multi-year bancassurance agreements in place for the distribution of life insurance products, giving JIC a competitive edge over most of its domestic peers. While JIC demonstrates a sound framework for identifying and managing underwriting-related risks, AM Best considers that risk management capabilities are not commensurate with the company's risk profile in areas including investments and capital management. The company is expected to take further steps to reduce its exposure to these risks over the short to medium term. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
Business Wire
24 minutes ago
- Business Wire
GEA Raises Forecast for Fiscal Year 2025 and Provides Positive Outlook
DUESSELDORF, Germany--(BUSINESS WIRE)--Due to a very positive operating performance in the first 6 months and expectations for the remainder of the financial year 2025, GEA Group Aktiengesellschaft is raising all guidance parameters based on preliminary figures as follows: Organic sales growth 2 to 4 percent (previously 1 to 4 percent), EBITDA-margin before restructuring expenses 16.2 to 16.4 percent (previously 15.6 to 16.0 percent) and ROCE 34 to 38 percent (previously 30 to 35 percent). The company will publish its complete statement for the 2nd quarter (half-year financial report) on August 7, 2025. 'Our positive development continues. The additional improvements are broad-based, supported by a favorable order situation as well as margin improvements and efficiency gains across the Group. Once again, we are thus demonstrating our strength in executing on our plans,' said GEA CEO Stefan Klebert. Alongside improving the profitability indicators EBITDA margin before restructuring expenses and ROCE, GEA also increased order intake and revenues on an organic basis compared to the prior-year quarter. This was particularly driven by a strong base business. The large order with a volume of between EUR 140 million and EUR 170 million announced by GEA on July 29 will only be booked in the second half of this year. 'Despite the current environment, GEA continues to perform very positively. We anticipate further interesting projects of all sizes in the second half of the year and expect to significantly accelerate our revenue growth in 2026 while further increasing profitability. Against this background, we are confirming our Mission 30 growth and profitability targets,' GEA CEO Stefan Klebert added. NOTES TO THE EDITOR More information about GEA To the GEA Media Center Follow GEA on LinkedIn, YouTube ABOUT GEA GEA is one of the world's largest suppliers of systems and components to the food, beverage and pharmaceutical industries. The international technology group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components and comprehensive services. For instance, every second pharma separator for essential healthcare products such as vaccines or novel biopharmaceuticals is produced by GEA. In food, every fourth package of pasta or every third chicken nugget are processed with GEA technology. With more than 18,000 employees, the group generated revenues of about EUR 5.5 billion in more than 150 countries in the 2024 fiscal year. GEA plants, processes, components and services enhance the efficiency and sustainability of customers' production. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company's purpose: 'Engineering for a better world.' GEA is listed on the German MDAX, the European STOXX® Europe 600 Index and is also a constituent of the leading sustainability indices DAX 50 ESG, MSCI Global Sustainability and Dow Jones Best-in-Class World. More information can be found online at pr@
Business Wire
an hour ago
- Business Wire
KBRA Comments on the Implications of the EU Trade Agreement for U.S. LNG
NEW YORK--(BUSINESS WIRE)--As part of the European Union's (EU) broader REPowerEU strategy to reduce dependence on Russian energy and under the terms of the recently announced U.S.-EU trade agreement, the EU has committed to purchasing $750 billion worth of U.S. energy over the next three years to meet demand. Abundant low-cost natural gas across the Permian, Eagle Ford, and Haynesville basins—combined with modest liquefaction fees and close proximity to liquefied natural gas (LNG) export facilities on the U.S. Gulf Coast (USGC)—continue to make U.S. LNG incredibly competitive. While there is currently no impact to KBRA's portfolio of LNG export facilities due to their contracted nature, future projects could be affected if they seek to monetize merchant cash flows. While the announcement is a positive development for U.S. natural gas producers, meeting export requirements at this scale presents significant challenges. In 2024, U.S. export capacity totaled 11.9 billion cubic feet per day (Bcf/d) across eight facilities, predominantly located along the USGC. The Department of Energy (DOE) has authorized a cumulative 55.3 Bcf/d of LNG exports as of June 30, 2025. Several export facilities currently under construction are expected to reach commercial operations date (COD) this year, with additional projects slated to reach COD later this decade. Further, up to eight U.S. LNG export facilities are anticipated to reach final investment decision (FID) by year-end 2025. While this additional capacity will support broader U.S. export goals, many of these facilities are already committed through letters of intent (LOI) or long-term contracts with international offtakers to secure financing. As a result, they are unlikely to have sufficient uncontracted capacity available to fulfill obligations under the recent trade agreement. About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1010640
